01
First-line treatment in advanced NSCLC
Evaluate EGFR exon 19 deletions, L858R, exon 20 insertions, ALK fusions, and ROS1 fusions at diagnosis to select variant-specific therapy according to stage, prior treatment, and current guidance.
Assay and specimen: Broad validated DNA NGS on FFPE tissue, supplemented with RNA-based fusion assays where appropriate; validated ALK IHC and orthogonal confirmation as indicated.
Clinical interpretation: Report the precise EGFR variant, fusion characteristics, prior tyrosine-kinase inhibitor exposure, and central nervous system involvement.
02
Acquired resistance and progression
At progression under tyrosine-kinase inhibitors, repeat testing can reveal secondary mutations, bypass alterations, or histologic transformation and may influence subsequent management.
Assay and specimen: Tissue re-biopsy where feasible; validated plasma ctDNA as a complementary approach when tissue access is limited.
Clinical interpretation: Negative plasma ctDNA does not exclude a resistance mechanism, particularly in low-shedding tumors. Tissue-based reassessment may be needed.
03
Test sequencing and tissue preservation
Coordinate required testing in small lung biopsies to reduce tissue depletion and delays in treatment decisions.
Assay and specimen: Document tumor fraction, panel depth and coverage, fusion-detection capability, and complementary DNA/RNA methods.
Clinical interpretation: PD-L1 alone is insufficient; assess relevant EGFR alterations and fusions before relying on first-line immunotherapy selection.